Latest Regulatory Approval News

ClearView Wealth’s acquisition by Zurich Financial Services Australia has cleared its final legal hurdle, triggering a trading halt and scheduled shareholder payouts including a special dividend and cash scheme consideration.

Acrux Limited’s FY26 receipts soared 960% to $5 million, fuelled by licensing milestones and growing generic sales, while FDA guidance clears the way for pivotal Phase III trials of its Female Testosterone therapy.

T&G Global has agreed to sell its T&G Fresh business in three transactions worth a combined enterprise value of NZD 72.65 million, aiming to sharpen its focus on premium apples and VentureFruit platforms while reducing debt.

Jade Gas Holdings has secured regulatory approvals for Mongolia’s first coal bed methane reserves, completed a A$12 million capital raise, and signed a non-binding A$1.1 billion collaboration agreement to fund initial development of its Red Lake gasfield.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

American West Metals (ASX: AW1) reported significant exploration breakthroughs at its West Desert Project in Utah and ongoing Pre-Feasibility Study progress at the Storm Copper Project in Nunavut, backed by a $10 million capital raise.

Pepper Money is set to become the servicer for a massive A$36 billion loan portfolio from HSBC Australia following its acquisition by a Blackstone-controlled entity, aligning with Pepper Money's strategy to expand its capital-light servicing business.

Blue Star Helium has completed the commissioning phase of its Pinon Canyon helium plant, secured a three-month helium offtake agreement with a major US buyer, and begun selling helium as it prepares for production ramp-up in the second half of 2026.

Skin Elements has secured an exclusive New Zealand distribution agreement for its ECO-Nurture bio-stimulant, raised $1.47 million through options and placement, and refreshed its board after shareholder votes.

Finder Energy has secured key regulatory approval for its KTJ Project in Timor-Leste and raised $27 million to advance development, positioning for a Final Investment Decision in Q3 2026.

The Supreme Court of New South Wales has approved Zurich’s acquisition of ClearView, setting a clear timetable for scheme implementation and shareholder payouts.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.